Overview

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Status:
NOT_YET_RECRUITING

Trial end date:
2034-02-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label phase II study with 2 parallel cohorts for frail patients with newly diagnosed multiple myeloma treated with daratumumab in combination with teclistamab and talquetamab. The main purpose of this study is to determine the progression free survival at 18 months in patients treated with teclistamab and daratumumab (Cohort 1) or talquetamab and daratumumab (Cohort 2).

Phase:

PHASE2

Details

Lead Sponsor:

European Myeloma Network B.V.

Collaborators:

EMN Trial Office S.r.l. Impresa Sociale
HOVON - Dutch Haemato-Oncology Association
Janssen Pharmaceutica N.V., Belgium
Nordic Myeloma Study Group
PETHEMA Foundation

Treatments:

daratumumab
talquetamab